MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Phase 2
Completed
Conditions
Pulmonary Fibrosis
Interventions
First Posted Date
2010-07-27
Last Posted Date
2019-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
198
Registration Number
NCT01170065
Locations
🇪🇸

Hospital Vall d'Hebron, Barcelona, Spain

🇨🇱

Instituto Nacional del Tórax, Santiago, Chile

🇧🇬

Special. Hospital for Active Treatment, Sv. Sofia 2nd Clinic, Sofia, Bulgaria

and more 54 locations

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: BIBW 2992 low dose
Drug: BIBW 2992 high dose 6 day
Drug: BIBW 2992 high dose
Drug: BIBW 2992 medium dose 6 day
Drug: BIBW 2992 medium dose
Drug: BIBW 2992 low dose 6 day
First Posted Date
2010-07-26
Last Posted Date
2014-06-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53
Registration Number
NCT01169675
Locations
🇨🇦

1200.92.1001 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada

🇨🇦

1200.92.1002 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2010-07-22
Last Posted Date
2016-09-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1549
Registration Number
NCT01167881
Locations
🇦🇹

1245.28.43003 Boehringer Ingelheim Investigational Site, Wien, Austria

🇺🇸

1245.28.10030 Boehringer Ingelheim Investigational Site, Draper, Utah, United States

🇺🇸

1245.28.10014 Boehringer Ingelheim Investigational Site, Rochester, New York, United States

and more 179 locations

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Renal Insufficiency
Interventions
Drug: Placebo
First Posted Date
2010-07-16
Last Posted Date
2014-06-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
741
Registration Number
NCT01164501
Locations
🇺🇸

1245.36.10014 Boehringer Ingelheim Investigational Site, Anaheim, California, United States

🇺🇸

1245.36.10012 Boehringer Ingelheim Investigational Site, Corpus Christi, Texas, United States

🇳🇱

1245.36.31004 Boehringer Ingelheim Investigational Site, Den Haag, Netherlands

and more 124 locations

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo identical to BI 10773 high dose
Drug: Placebo identical to BI 10773 low dose
First Posted Date
2010-07-09
Last Posted Date
2014-06-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1504
Registration Number
NCT01159600
Locations
🇨🇦

1245.23.20033 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada

🇺🇸

1245.23.10001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States

🇺🇸

1245.23.10127 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States

and more 145 locations

Relative Bioavailability of Olodaterol and Fluconazole

Phase 1
Completed
Conditions
Healthy
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2010-06-30
Last Posted Date
2014-06-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
35
Registration Number
NCT01153724
Locations
🇩🇪

1222.48.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Terminated
Conditions
Venous Thromboembolism
Arthroplasty, Replacement
Interventions
First Posted Date
2010-06-30
Last Posted Date
2023-10-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
167
Registration Number
NCT01153698
Locations
🇦🇹

1160.118.43007 Boehringer Ingelheim Investigational Site, Wien, Austria

🇦🇹

1160.118.43004 Boehringer Ingelheim Investigational Site, Braunau, Austria

🇦🇹

1160.118.43016 Boehringer Ingelheim Investigational Site, Stolzalpe, Austria

and more 4 locations

Relative Bioavailability of of Olodaterol and Ketoconazole

Phase 1
Completed
Conditions
Healthy
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2010-06-30
Last Posted Date
2014-04-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT01153711
Locations
🇩🇪

1222.47.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2010-06-29
Last Posted Date
2024-12-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
94
Registration Number
NCT01152450
Locations
🇱🇻

205.420.37101 Boehringer Ingelheim Investigational Site, Riga, Latvia

🇱🇻

205.420.37103 Boehringer Ingelheim Investigational Site, Riga, Latvia

🇦🇹

205.420.43001 Boehringer Ingelheim Investigational Site, Wels, Austria

and more 12 locations

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Neoplasms
Interventions
First Posted Date
2010-06-29
Last Posted Date
2014-06-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
94
Registration Number
NCT01152437
Locations
🇬🇧

1200.74.44009 Boehringer Ingelheim Investigational Site, London, United Kingdom

🇬🇧

1200.74.44005 Boehringer Ingelheim Investigational Site, Bristol, United Kingdom

🇬🇧

1200.74.44003 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy